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Abstract
Background and aims: Individual MRI markers of cerebral small vessel disease are associated with gait impairment.
The impact of total cerebral small vessel disease-related brain damage, expressed by a cerebral small vessel disease MRI
burden score, on mobility after stroke, has not been considered, although this score gives a better representation of the
overall effect of cerebral small vessel disease on the brain. We determined if the total cerebral small vessel disease
burden is associated with gait impairment three years after minor stroke.
Methods: In total, 200 patients with minor lacunar or non-lacunar stroke (NIHSS 7) underwent a brain MRI at
presentation. Presence of lacunes, white matter hyperintensities, cerebral microbleeds, and perivascular spaces were
summed in a total cerebral small vessel disease MRI burden score (range 0–4). Gait disturbances, measured by timed-up-
and-go test and self-reported stroke impact scale mobility domain were assessed three years after stroke. We tested
associations adjusted for key variables by linear regression analysis.
Results: Total cerebral small vessel disease burden was not associated with gait impairment after minor stroke in all
patients, nor in lacunar stroke patients (n¼ 87). In non-lacunar stroke patients (n¼ 113), total cerebral small vessel
disease burden was associated with lower stroke impact scale mobility domain scores, independent of age, vascular risk
factors, and stroke severity (unstandardized B 4.61; 95% CI 8.42; 0.79, p< 0.05).
Conclusion: Patients with non-lacunar stroke and a higher total cerebral small vessel disease burden have more subjective
mobility impairment three years after stroke. The total cerebral small vessel disease MRI burden score is a possible marker
to identify patients at risk for subjective gait impairment. These findings should be confirmed in larger studies.
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Introduction
Cerebral small vessel disease (cSVD) causes MRI vis-
ible brain damage, including white matter hyperinten-
sities (WMH), lacunes, perivascular spaces (PVS), and
cerebral microbleeds (CMB).1,2 The burden of cSVD on
public health is substantial: cSVD is a leading cause of
cognitive impairment, dementia, and stroke.3
Less recognized, cSVD is also related to gait disturb-
ances4,5 and worse functional outcome after stroke.6–8
Several studies have demonstrated that individual MRI
markers of cSVD, including WMH and CMB, are
related to gait impairment.4,5,9,10 However, most of
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these studies have focused on individual MRI features
of cSVD rather than recognizing the impact of total
cSVD-related brain damage. A total cSVD burden
score, based on visual MRI feature recognition, might
better capture the relation between risk factors and
brain injury11,12 or the overall effect of cSVD on cog-
nitive function.13,14 Whether the total cSVD MRI
burden score is associated with gait impairment after
stroke is unknown.
Aims
We aimed to determine if overall cSVD-related brain
damage, measured by a total cSVD MRI burden score,
is associated with gait disturbances, objectively mea-
sured by the timed-up-and-go (TUG) test and subject-
ively assessed by self-reported stroke impact scale (SIS)
mobility domain score, three years after minor ischemic
stroke. In a secondary analysis, we also tested the asso-
ciation between the total cSVD burden scale and func-
tional stroke outcome, measured by the modified
Rankin Scale (mRS).
Methods
For a detailed description, see the online-only
Supplemental Data. In short, we used data from a pro-
spective observational study in patients with minor
ischemic stroke (Mild Stroke Study-2).15–17 The study
was approved by the Scotland and Lothian Research
Ethics Committee (ref 09/S1101/54) and all patients
gave written informed consent.
All patients underwent a 1.5 Tesla brain MRI scan,
which was assessed for presence of an acute symptom-
atic lacunar or non-lacunar infarct. Baseline MRI was
also rated for presence of lacunes, WMH, CMB, and
basal ganglia PVS, all according to the Standards for
Reporting Vascular Changes on Neuroimaging
(STRIVE) for reporting studies in cSVD.2 These MRI
markers were summed in an ordinal ‘‘total cSVD
burden score’’ (with a range of 0–4) by counting pres-
ence of each of these four MRI features.12,14 Definition
of MRI markers and details on cSVD burden score is in
the online-only Supplemental Data.
Three years after stroke, gait disturbances were
objectively measured by TUG test and subjectively
assessed by self-reported SIS mobility domain score.
The TUG test measures time (in seconds) to get up
from a chair, walk 3m, turn around, walk back, and
sit back down.18 The SIS is a stroke-specific, self-
reported assessment questionnaire with eight different
domains, including mobility. The SIS mobility domain
score (range 0–100) was calculated from nine mobility
items by using a validated logarithm.19 A low SIS
mobility domain score reflects a high impact on
health-related quality of life. Functional disability out-
come was assessed by mRS at three years after stroke.
We tested associations adjusted for key vari-
ables (age, gender, vascular risk factors, and stroke
severity (NIHSS)) by linear regression analysis
(log-transformed TUG, SIS) and by logistic regression
analysis (mRS). Statistical significance was set at
p< 0.05 (2-tailed).
Results
Patients and baseline characteristics
In total, 200 of 264 minor stroke patients had a three-
year clinical follow-up (Figure 1). For a detailed
description, see the online-only Supplemental Data.
Baseline clinical and MRI characteristics are shown in
Table 1.
Association between total cSVD burden and
(log-transformed) TUG test
The TUG test was performed in 145 patients (73%)
with a median time of 10.7 (range 3.2–38.6) s.
Patients who completed the TUG test were significantly
younger than patients who did not do the TUG test
(n¼ 55) (65.5 11.0 vs. 70.2 11.8 years, p< 0.05);
vascular risk factors and MRI characteristics did not
differ between groups. The median time did not differ
between lacunar stroke and non-lacunar stroke patients
(10.9 (range 6.5–38.6) vs. 10.6 (range 3.2–26.7) s,
p¼ 0.63). The total cSVD burden was not associated
with log-transformed TUG test (linear regression ana-
lysis; Table 2).
Association between total cSVD burden and
self-reported SIS mobility domain
The self-reported SIS mobility domain questionnaire,
completed in 165 patients (83%), had a median score
of 77.8 (range 22.2–100). The median SIS mobility
score did not differ between the lacunar stroke and
non-lacunar stroke group (both median of 77.8 (range
22.2–100), p¼ 0.78). Table 3 shows associations
between total cSVD burden and SIS mobility domain
score. No association was found between total cSVD
burden score and SIS mobility domain score in the total
minor stroke group, nor in lacunar stroke patients.
In non-lacunar stroke patients, total cSVD burden
was associated with worse scores on the SIS mobil-
ity domain (unstandardized B 6.68, 95% CI
9.96;3.40, p< 0.01). This association remained sig-
nificant after adjustment for age, gender, vascular risk
factors, and stroke severity (unstandardized B 4.61;
95% CI 8.42;0.79, p< 0.05).
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There was a strong correlation between objectively
measured TUG test and subjectively assessed SIS
mobility domain score: correlation coefficient 0.58
(n¼ 142; p< 0.00).
Association between total cSVD burden and mRS
At three years of follow-up, 200 patients had mRS
measurement with a median mRS of 1 (range 0–5).
One hundred seventy-four patients (87%) were func-
tionally independent (mRS 2) and 26 patients (13%)
were functionally dependent (mRS 3–5). The total
cSVD burden was associated with mRS> 2 in the
total stroke group (OR 1.47; 95% CI: 1.05–2.06;
p< 0.05). However, this association lost significance
after adjusting for age, gender, vascular risk factors,
and baseline stroke severity (OR 1.21; 95% CI 0.79–
1.87, p¼ 0.38). No association was found between total
cSVD burden and mRS in non-lacunar stroke patients
(n¼ 113), nor in the lacunar stroke group (n¼ 87).
Discussion
Our study did not find an association between total
cSVD burden and objectively measured gait
disturbances, nor with subjectively assessed gait impair-
ment in the total minor stroke group three years after
stroke. However, in non-lacunar stroke patients, the
total cSVD burden score was associated with lower
self-reported SIS mobility domain scores three years
after stroke, independent of stroke severity.
Previous neuroimaging studies have consistently
demonstrated that individual MRI markers of
cSVD are related to gait impairment,4,5,9,10,20 mainly
in community-dwelling subjects rather than stroke
patients. The Radboud University Nijmegen Diffusion
Tensor and Magnetic Resonance Imaging Cohort
(RUNDMC) study, which included patients with clin-
ical cSVD (including stroke and gait impairment),
showed that WMH, number of lacunes, and CMB
were associated with concurrent gait dysfunction, includ-
ing impaired gait velocity and a prolonged TUG test.5,9
The leukoaraiosis and disability (LADIS) study showed
that WMH were associated with concurrent deterior-
ation of gait function, especially at older age.4,10
Although these studies have shown that individual
MRI markers of cSVD are independently linked to con-
current gait impairment, these cSVD markers rarely
occur in isolation on MRI. There is increasing evidence
that a total cSVD MRI burden score, which
Figure 1. Patient recruitment data of MSS II 3-year follow-up study. MSS II: Mild Stroke Study-2.
264 patients in MSS II Study
64 patients lost of follow-up 
• 22 patients died
• 16 patients declined
• 26 patients not contactable 
200 patients with 3 year clinical follow-up
including mRS scores
157 patients had in 
person follow-up 
43 patients declined a 
visit, but provided 
some follow-up data 
145 had TUG test 
165 completed mobility 
domain SIS questionnaire 
• 4 patients refused 
• 1 patient with wheelchair
• 1 patient with leg 
amputation
• 6 patients had unsafe 
mobility
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Table 1. Characteristics of 200 minor stroke patients who had a three-year clinical follow-up
Total stroke group
N¼ 200
Lacunar stroke
N¼ 87
Non-lacunar stroke
N¼ 113
Demographics
Age (years; mean SD) 66.8 11.4 64.3 11.1 68. 7 11.3*
Male (%) 112 (56) 49 (56) 63 (56)
NIHSS (range) 1 (0–7) 1 (0–7) 1 (0–5)*
Hypertension (%) 145 (73) 60 (69) 85 (75)
Diabetes mellitus (%) 20 (10) 7 (8) 13 (12)
Hyperlipidaemia (%) 126 (63) 56 (64) 70 (62)
Smoking (%) 61 (31) 31 (36) 30 (27)
MR imaging
Presence of lacunes 49 (25) 30 (35) 19 (17)*
Presence of brain microbleeds 33 (17) 18 (21) 15 (13)
Moderate-severe BG PVS (%) 100 (50) 48 (55) 52 (46)
Periventricular WMH Fazekas (%)
0 14 (7) 5 (6) 9 (8)
1 89 (44) 40 (46) 49 (43)
2 54 (27) 25 (29) 29 (26)
3 43 (22) 17 (20) 26 (23)
Deep WMH Fazekas (%)
0 19 (9) 7 (8) 12 (11)
1 96 (48) 42 (48) 54 (48)
2 52 (26) 27 (31) 25 (22)
3 33 (17) 11 (13) 22 (19)
Extensive WMH (%) 85 (43) 38 (44) 47 (42)
Total cSVD burden scale
0 64 (32) 24 (28) 40 (36)
1 52 (26) 20 (23) 32 (28)
2 47 (24) 23 (26) 24 (21)
3 27 (13) 12 (14) 15 (13)
4 10 (5) 8 (9) 2 (2)
*p< 0.05. Lacunar stroke versus non-lacunar stroke patients.
SD: standard deviation; BG: basal ganglia; PVS: perivascular spaces; WMH: white matter hyperintensities; cSVD: cerebral small vessel disease.
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summarizes individual cSVD markers in a compound
scale, might better reflect the global overall effect of
cSVD on the brain.11–14,20,21 A study22 in older subjects
with vascular risk factors showed that concurrent gait
function, measured by Unified Parkinson’s Disease
Rating Scale,23 was associated with total cSVD
burden. This was the first study looking at concurrent
gait function and overall cSVD burden (but not after
stroke), although the cSVD burden score was incom-
plete as they did not include PVS. Recently, a study20 in
community-dwelling older subjects found that WMH
and the total cSVD score were independently associated
with slower gait speed assessed by a six-meter walk test.
Contrary to these positive results in larger studies,
mostly in subjects without stroke, we did not find any
association between total cSVD burden and gait dis-
turbances, measured by TUG test. There are several
differences between studies. Our sample size was smal-
ler, although the direction of the effect was consistent
with an association between total cSVD burden and
slowing gait. Second, we used the TUG test, and did
not perform functional gait analysis, which would be a
more quantitative and more sensitive method in assess-
ing (subtle) mobility impairment. However, the TUG
test is a valid outcome measurement that assesses basic
functional mobility in routine practice,18 is representa-
tive of daily activities, also in stroke patients24 and
is conceptually similar to the six-meter walk. Third,
our minor stroke population was somewhat younger
compared to several previous studies with commu-
nity-dwelling subjects.4,10,20,22 Last, the LADIS4,10
and RUNDMC5,9 study selected patients based on
presence of WMH. This could have led to a higher
WMH burden in these cohorts compared to ours.
However, as the measurement methods were different
(volumetric versus visual scales), it is difficult to com-
pare. In our cohort, 43% had extensive WMH (repre-
sented by 1 point in cSVD burden score), while 54%
had mild WMH and only 3% had no WMH at all.
Subjectively measured mobility impairment was
associated with the total cSVD burden score in non-
lacunar stroke patients. The self-reported SIS mobility
domain score was available for more patients and
therefore increased power. The SIS is a valid and reli-
able comprehensive stroke-specific health outcome
measurement, especially in minor strokes19 and cap-
tures the impact of stroke on multiple domains, includ-
ing mobility.25 We found a strong correlation between
Table 3. Association between total cSVD burden and stroke impact scale mobility domain score in minor stroke patients
Stroke impact scale mobility domain score, unstandardized B (95% CI)
Total cSVD score N Unadjusted Model 1 Model 2 Model 3
Total minor
stroke group
165 3.05* (5.65;0.45) 1.76 (4.51;1.00) 1.55 (4.35;1.25) 0.95 (3.77;1.86)
Lacunar stroke 73 0.50 (3.71;4.71) 1.40 (3.26;6.06) 1.20 (3.43;5.83) 2.22 (2.15;6.60)
Non-lacunar
stroke
92 6.68y (9.96; 3.40) 4.69* (8.22; 1.16) 4.30* (8.11; 0.49) 4.61* (8.42; 0.79)
Note: Model 1 adjusted for age and gender. Model 2 adjusted for age, gender and vascular risk factors (diabetes mellitus, hypertension, hyperchol-
esterolemia and smoking). Model 3 adjusted for age, gender, vascular risk factors and NIHSS. Multiple hierarchical linear regression analysis, *p< 0.05,
yp< 0.01.
cSVD: cerebral small vessel disease; CI: confidence interval.
Table 2. Association between total cSVD burden and log-transformed timed-up-and-go test in minor stroke patients
Log-transformed timed-up-and-go test, unstandardized B (95% CI)
Total cSVD score N Unadjusted Model 1 Model 2 Model 3
Total minor stroke group 145 0.02 (0.00;0.04) 0.01 (0.01;0.03) 0.01 (0.02;0.03) 0.00 (0.02;0.02)
Lacunar stroke 62 0.00 (0.03;0.03) 0.00 (0.03;0.04) 0.00 (0.03;0.04) 0.00 (0.04;0.03)
Non-lacunar stroke 83 0.03* (0.00;0.05) 0.01 (0.02;0.04) 0.01 (0.02;0.04) 0.01 (0.02;0.04)
Note: Model 1 adjusted for age and gender. Model 2 adjusted for age, gender and vascular risk factors (diabetes mellitus, hypertension, hyperchol-
esterolemia and smoking). Model 3 adjusted for age, gender, vascular risk factors and NIHSS. Multiple hierarchical linear regression analysis, *p< 0.05.
cSVD: cerebral small vessel disease: CI: confidence interval.
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TUG test and SIS mobility domain score, meaning that
perceived mobility disturbances are relevant and
furthermore, mobility is a broader function than what
is measured by the TUG test. The associations we
found were present in non-lacunar stroke patients,
but not in lacunar stroke patients. A possible explan-
ation could be that stroke subtype is a moderator of the
effect of cSVD on outcome; a non-lacunar ischemic
stroke could make the brain more vulnerable to the
impact of cSVD. Furthermore, as we did not find an
association between the total cSVD burden score and
mRS three years after minor stroke, it should be noted
that any association between the total cSVD burden
score and mobility impairment is not simply because
of a co-association with worse functional stroke out-
come after minor stroke. Therefore, our results indicate
that minor non-lacunar stroke patients with a high total
cSVD load on MRI are prone to report more often
subjective mobility disturbances three years after
minor stroke, independent of stroke severity.
Our study has several limitations. Although this is
the first study which investigates if the total cSVD
burden score could be a possible marker in predicting
gait impairment in patients with minor stroke, our
sample is small for a common disease like stroke.
A larger study is warranted to confirm if the association
between gait speed and total cSVD burden reaches sig-
nificance in a larger sample. We measured gait function
at three years after stroke onset, so it could be that
significant disabled patients may not have participated
in clinical follow-up, leading to selection bias. We did
not have gait function at baseline, so we could not
explore gait decline, nor correct for pre-existing gait
disturbances.
A strength of our study is that it was prospective,
systematic and assessments were blinded. We used stan-
dardized international consensus criteria2 to describe
cSVD imaging findings and provide predictive rather
than just concurrent mobility data. Furthermore, we
used an overall cSVD-related brain damage score.
The total cSVD burden score is a pragmatic and
simple visual score, which gives a more comprehensive
view of the impact of cSVD on the brain.12 Patients
with minor (non-disabling) stroke are an ideal stroke
subgroup for exploring the relationship between cSVD
burden and gait disturbances, as the impact of stroke
itself on outcome measurements is probably reduced.
Summary
The total cSVD burden was not associated with object-
ively measured gait impairment, nor with subjectively
assessed gait disturbances in minor stroke patients, nor
in lacunar stroke patients. As patients with non-lacunar
stroke and a higher total cSVD burden report more
often subjective mobility impairment three years after
stroke, the total cSVD burden score is a possible
marker to identify non-lacunar stroke patients at risk
for subjective gait impairment. These findings should be
confirmed in a larger study.
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